PainChek hasannounced that its pain assessment and monitoring tech is a giant step closer to being protected in Europe. Get your health news here.
European Patent Office (EPO) has issued a Notice of Acceptance for PCK’s patent application.
Once approved, the patent will award the ASX biotech with exclusive rights to the commercialisation of its technology across the 39 member states of the European Patent Organisation, until 2035.
For the latest health news, sign up here for free Stockhead daily newsletters
“This acceptance letter is the precursor to a fully granted patent, securing our intellectual property in the significantly large European markets, which is key to our global strategy,” said PainChek CEO Philip Daffas.
“This includes the UK where we continue to demonstrate growing adoption of PainChek.”
The new patent is in addition to the existing patents granted in the USA, Japan, and China providing intellectual property protection of PainChek’s technology across the largest healthcare markets in the world.
The PainChek App uses artificial intelligence (AI) and facial recognition to detect pain in those who cannot self-report, giving a voice to those who cannot verbalise pain.
For those who can self-report, PainChek Universal also includes access to the Numerical Rating Scale, a well-established standard used to document pain levels.
HeraMed signs deal with Telstra
HeraMed (ASX:HMD) has signed a partner agreement with Australia’s largest e-health provider, Telstra Health.
The agreement allows HeraCARE to become the first remote maternity solution to join Telstra Health’s Smart Marketplace.
MORE FROM STOCKHEAD: 4DX wins key FDA clearance| Turning over new (cannabis) leaf | Orphan Drug designation for Argenica
This is significant because Telstra Health is Australia’s largest provider of digital solutions and services to healthcare providers and governments across the care continuum, with more than a decade of experience scaling virtual care solutions across Australia.
Integration of HeraCARE is now under way, with an expected launch in Q1 of 2024.
At 2pm Tuesday (AEDT), HMD’s share price was up more than 4 per cent for the day.
AdAlta’s interim Phase 1 result
AdAlta (ASX:1AD) hasannounced interim results of its Phase I extension clinical study of its lead asset, AD-214.
The results were positive, and reinforced the safety profile and potential efficacy of the 10 mg/kg dose of AD-214, which further de-risks the planned Phase II studies in Idiopathic Pulmonary Fibrosis.
Study investigators reported no dose limiting toxicity, no need to interrupt doses, and no requirement to administer medication to manage infusion reactions.
The frequency of mild infusion-related reactions appears lower than that observed at 5mg/kg in the original Phase I study.
Results also show that the bioavailability of AD-214 and the blocking of its target receptor, CXCR4 (receptor occupancy), was in line with prior single dose studies.
In addition, the immune response to AD-214 was lower this time than observed in prior multi-dose studies.
“These interim results are very much in-line with our expectations,” said AdAlta CEO, Tim Oldham.
“We are sharing these results with potential partners, and anticipate that they will further enhance our existing out-licensing and project financing discussions.”
Full safety and tolerability results are due in the March quarter of 2024.
On the news, Adalta’s share price was up more than 5.5 per cent at 2pm Tuesday (AEDT).
Visit Stockhead, where ASX small caps are big deals
Avita updates full year guidance
Avita Medical (ASX:AVH) dropped more than 7 per cent on Tuesday morning after announcing an update to its full year 2023 guidance.
By 2pm (AEDT), the loss for the day was nearly 10 per cent.
The update was driven by slower-than-anticipated progress in its customer’s value analysis committee (VAC) processes. VACs are groups that manage medical and surgical product use within a hospital.
As a result of these delays, Avita is revising its expected full year 2023 commercial revenue from the previously disclosed range of $51 million to $53 million, to a range of about $49.5 million to $50.5 million.
This reflects growth rates of approximately 45 per cent and 48 per cent, respectively, over the same period in 2022.
“Our expanded label for full-thickness skin defects opens up an abundance of exciting applications,” said Jim Corbett, CEO of Avita.
“With a wider range of potential uses, more clinicians within the hospital are engaged in the VAC process, leading to longer hospital approval timelines.”
Corbett said that although the VAC processes were taking longer, he expected that once completed, the process would yield positive approvals and an expanded market opportunity for the company.
This content first appeared on stockhead.com.au
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox. Click here
Source link
credite